Thyreogen
At a glance
PeptiGuide dataset · reviewed Aug 2026
What it is
Thyroid-focused bioregulator supplement with preclinical evidence only.
Status
Preclinical
Typical dose
10–20mg
Researched for
Thyroid function, metabolism, thyroid health
Trial progress
- PrePreclinical
- IPhase I
- IIPhase II
- IIIPhase III
- IVPhase IV
- FDAFDA approved
Preclinical - Promising animal research, limited human data
Use the tools
Stay current
Get updates on Thyreogen
New studies, regulatory decisions and data corrections - delivered when they land.
In plain language
- Thyreogen is described as a cytomax thyroid bioregulator supplement made from short calf-thyroid peptides.
- The source does not provide a defined amino-acid sequence.
- It is listed as not FDA approved, with evidence status.
- Source-reported use areas include thyroid function, metabolism, and thyroid health.
- Product-specific clinical evidence is limited, and claims remain unproven.
How it's thought to work
Thyreogen is described under the Khavinson bioregulator framework. In that model, short tissue-derived peptides are hypothesized to enter cells and influence gene-expression programs, potentially through DNA-associated effects. The source reports thyroid-focused vendor claims involving thyroid-cell metabolism and T3, T4, and calcitonin output, but it also states that a Thyreogen-specific receptor, pathway, or independently established mechanism has not been mapped.
What the research shows
Where the research stands
The source places Thyreogen within the broader Khavinson bioregulator literature, which includes Russian publications and review-level discussions of short peptides as possible epigenetic regulators. It also states that evidence directly testing Thyreogen as a specific product is sparse, with no registered randomized placebo-controlled human trials for thyroid disease identified in the source material. Reported animal or family-level endocrine and geroprotective findings should therefore be treated as hypothesis-generating rather than proof for Thyreogen itself.
What it shows
✓ Animal studies
Promising animal research, limited human data
△ Limitations
Animal study doses may not translate directly to humans.
Bottom line: Preclinical research; approved in Russia as a supplement Not FDA approved
Typical dosing
CommunityCommunity dataset10–20 mg
daily
Community-reported dosing for a thyroid bioregulator; source notes possible thyroid hormone effects and limited safety evidence.
Research dosing
Animal studies onlyAnimal studies only - may not translate to humans
Doses observed in studies
10-20 mg daily
Animal study doses may not translate directly to humans.
- Duration
- 10-30 day cycles
- Administration
- Oral capsules or sublingual
Timing & administration
Best time to take
Morning on an empty stomach
Once or twice daily
Food recommendation
Take on an empty stomach
Why this timing?
The source says peptide bioregulators are commonly timed away from food because fasted use is presented as supporting absorption.
Possible side effects
Not everyone experiences these. Individual responses vary with dose, duration, and personal factors.
- Generally well tolerated
- May affect thyroid hormone levels
- Limited safety data outside Russia
- Not FDA approved
Not everyone experiences side effects, and severity can vary by context, purity, route, and individual health factors.
Sources
Frequently asked questions
One open dataset
Every fact on this page - doses, side effects, references - comes from the same PeptiGuide dataset that powers the Tracker, Compare, and the Lab.
Browse the datasetEducational resource, not medical advice. Talk to your clinician before acting on anything here.
Community discussion
Comments are moderated before they appear. Keep it evidence-focused.